RAMM Pharma Corp.
RAMM
CNSX
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -32.10% | 6.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -32.10% | 6.05% | |||
| Cost of Revenue | -85.12% | 28.71% | |||
| Gross Profit | 113,533.33% | -99.72% | |||
| SG&A Expenses | 102.02% | -1.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 1,290.91% | -36.54% | |||
| Total Operating Expenses | 14.78% | 11.13% | |||
| Operating Income | -58.43% | -16.31% | |||
| Income Before Tax | -1,252.77% | -376.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,254.79% | -160.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,254.79% | -160.93% | |||
| EBIT | -58.43% | -16.31% | |||
| EBITDA | -72.24% | -26.59% | |||
| EPS Basic | -1,250.00% | -166.67% | |||
| Normalized Basic EPS | -366.67% | 8.70% | |||
| EPS Diluted | -1,250.00% | -166.67% | |||
| Normalized Diluted EPS | -366.67% | 8.70% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||